Clinical Trials
31 trialsNCT05320198 2026-05-13
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
Phase 1/2 Recruiting
NCT06499285 2026-05-13
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Phase 3 Recruiting
NCT04256317 2026-04-30
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
NCT04582539 2025-10-22
LIMBER
Incyte Corporation
Phase 1/2 Terminated
NCT07145411 2025-08-28
HOPE
Ossium Health, Inc.
Recruiting
NCT03175978 2024-05-21
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
IGF Oncology, LLC
Phase 1/2 Terminated
NCT05927012 2023-11-24
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Keros Therapeutics, Inc.
Phase 2 Withdrawn
NCT02065869 2023-09-29
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT04631211 2023-05-25
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
Phase 2 Terminated
NCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT01736683 2022-10-24
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02477878 2022-07-12
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
Phase 1 Active not recruiting
NCT03301168 2022-07-12
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02631070 2021-12-17
MEDALIST
Celgene
Phase 3 Completed
NCT04429191 2021-06-11
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Jasper Therapeutics, Inc.
Phase 1 Unknown
NCT00020969 2020-10-05
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
CTI BioPharma
Phase 2 Terminated
NCT01241500 2020-06-30
ONTIME
Traws Pharma, Inc.
Phase 3 Completed
NCT01928537 2020-06-30
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Traws Pharma, Inc.
Phase 3 Completed
NCT01295710 2019-04-09
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Neovii Biotech
Phase 3 Completed
NCT00854945 2017-06-26
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Traws Pharma, Inc.
Phase 1/2 Completed
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed
NCT01461538 2016-03-04
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seagen Inc.
Phase 2 Completed
NCT00109538 2015-05-01
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT00081055 2014-12-04
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Mesoblast, Ltd.
Phase 2 Withdrawn
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated
NCT00004047 2012-05-16
Chemotherapy in Treating Patients Who Have Hematologic Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00596999 2012-04-10
HPDSC
Celgene
Unknown
NCT00179621 2011-04-14
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
Celgene
Phase 3 Completed